A meta-analysis led by Roswell Park's Muhammad Awidi, MD, has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors before or after a solid-organ transplant. The study will be featured as an oral abstract during at the American Society of Clinical Oncology Annual Meeting in Chicago.

New research on children diagnosed with acute lymphoblastic leukemia shows that the longer a patient’s BMI falls within the overweight/obese category during treatment, the greater the risk of relapse and the lower the chance of survival.

Roswell Park announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data. Four studies that incorporate SurVaxM are currently underway at Roswell Park and other centers nationally.